Shin Nippon Biomedical Laboratories Ltd
NAGATA Ichiro serves as Executive Vice President at 新日本科学 since June 2020, contributing to roles that include Vice President of the Preclinical Division and Executive Board Member in the CEO office. NAGATA is also the CEO of AMAFURU&Co. and previously held the position of Chief Executive Officer at Gemseki Inc. from February 2021 to June 2023. NAGATA's medical background includes experience as a Medical Doctor at Medipolis Proton Therapy and Research Center and as an intern at 順天堂医院. NAGATA's academic credentials feature a Master in Hospitality Administration from Cornell University, an MBA from 京都大学, a PhD in Radiology from 鹿児島大学, an MD from Juntendo University, and a BS in Biochemistry and Molecular Biology from Boston University, alongside completing a high school diploma from Lawrence Academy.
This person is not in any teams
This person is not in any offices
Shin Nippon Biomedical Laboratories Ltd
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.